Latest Health News

Wellnex Life Limited announces key board and management changes following its successful AIM Market dual listing, including the resignation of its Non-Executive Chairman and appointment of a joint CEO to drive growth.

Biome Australia is expanding its health portfolio with Activated Therapeutics, a new practitioner-only brand launching four evidence-based natural medicine products in Q4 2025.

HMC Capital has unveiled an ambitious plan to grow its assets under management to over $50 billion within the next 3-5 years, supported by strong fundraising and diversified investment verticals. The company’s FY25 outlook remains solid, underpinned by operational growth and strategic initiatives across real estate, digital infrastructure, and energy transition.

Epsilon Healthcare reports ongoing operational challenges post-voluntary administration while unveiling a new pharmacy subsidiary aimed at diversifying revenue streams and rebuilding market confidence.

Healius Limited has announced a special fully franked dividend of AUD 0.413 per ordinary share, signaling confidence in its financial position despite the ongoing suspension of its Dividend Reinvestment Plan.

Healius Limited has announced a fully franked special dividend of 41.3 cents per share totaling approximately $300 million, alongside a new $300 million three-year syndicated bank facility replacing its previous $680 million arrangement.

Enlitic Inc. has been reinstated to trading on the ASX following its announcement of a new equity raise, signaling renewed investor interest in the health technology firm.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

4DMedical has landed a significant commercial contract with Intermountain Health to deploy its FDA-cleared Pulmonary Hypertension Analysis (PHA™) product, marking a key milestone in its U.S. expansion through a strategic Microsoft-backed partnership.

Bio-Gene Technology Limited has raised $2.1 million through a placement and launched a Share Purchase Plan to fund critical safety studies for its flagship insecticide Flavocide®, alongside development of Qcide and strategic initiatives.

City Chic Collective faces a challenging US market due to steep tariff hikes on Chinese imports, prompting a strategic pause on new stock and a revised FY25 revenue outlook. Meanwhile, its ANZ operations continue robust growth, balancing the Group’s overall performance.

Motio Limited has upgraded its FY25 financial guidance following robust trading after the April period, raising revenue and cash EBITDA targets while maintaining a solid cash position.